Other Sarcomas Gene-Edited Cell Models for Drug Discovery

Sarcomas are rare mesenchymal tumors accounting for approximately 1% of all adult cancers and 15% of pediatric cancers (WHO, 2022). The global incidence is about 5 per 100,000 person-years, with over 50 distinct histological subtypes. The 5-year survival rate for localized disease is around 80%, but drops to 15-20% for metastatic or recurrent disease (NCI SEER data, 2023). Key risk factors include genetic predisposition syndromes (Li-Fraumeni, neurofibromatosis type 1), prior radiation therapy, and chronic lymphedema. The heterogeneity of sarcomas presents a major challenge for clinical management and underscores the need for subtype-specific research models.

Sarcomas are ideal for mechanistic studies due to their well-defined genetic drivers (e.g., translocations, copy number alterations) and relatively low mutational burden compared to carcinomas. Public datasets such as TCGA-SARC (n=261) and cBioPortal provide comprehensive genomic, transcriptomic, and clinical data. Key open questions include the role of tumor microenvironment, immune evasion mechanisms, and the development of resistance to targeted therapies. Gene-edited cell models are essential tools to functionally validate these drivers and test novel therapeutic strategies.

The pathogenesis of sarcomas involves several key pathways:

1. TP53/RB1 pathway: Loss of tumor suppressors TP53 and RB1 is common in high-grade sarcomas, leading to genomic instability and uncontrolled cell cycle progression.

2. PI3K/AKT/mTOR pathway: Activating mutations in PIK3CA or loss of PTEN drive cell survival and proliferation.

3. Receptor tyrosine kinase (RTK) signaling: Amplification or mutation of KIT, PDGFRA, or EGFR is seen in specific subtypes (e.g., gastrointestinal stromal tumors).

4. Wnt/beta-catenin pathway: Aberrant activation contributes to osteosarcoma and synovial sarcoma.

Data from TCGA-SARC (2017) and COSMIC v98.

Key deregulated networks in sarcomas include:

• • PI3K/AKT/mTOR: Hyperactivation via PIK3CA mutation, PTEN loss, or AKT amplification. Promotes cell growth and survival.
• • MAPK/ERK: Activated by RTK mutations (KIT, PDGFRA) or RAS mutations. Drives proliferation.
• • Cell cycle control: Loss of TP53, RB1, or CDKN2A leads to unchecked G1/S transition.
• • DNA damage repair: Mutations in ATRX, BRCA1/2, or ATM impair homologous recombination repair, creating synthetic lethality opportunities (e.g., PARP inhibitors).
• • Immune evasion: Upregulation of PD-L1 and recruitment of immunosuppressive cells (Tregs, MDSCs) in the tumor microenvironment.

Organoid cultures derived from patient samples better recapitulate tumor heterogeneity and microenvironment interactions, making them valuable for drug testing and personalized medicine studies.

Common animal models for sarcoma research include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor fragments into immunodeficient mice. Retains tumor heterogeneity and stroma.
• • Genetically engineered mouse models (GEMM): Conditional knockout of Tp53 and Rb1 in mesenchymal stem cells leads to osteosarcoma development.
• • Induced models: Injection of sarcoma cell lines (e.g., U-2 OS) into mice to form subcutaneous or orthotopic tumors.
• • Zebrafish models: Transgenic lines expressing mutant KIT develop GIST-like tumors, enabling high-throughput drug screening.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53 knockout in U-2 OS cells to study loss-of-function effects on genomic stability.
• • KRAS G12D knock-in in HT-1080 cells to model oncogenic RAS signaling.
• • CDKN2A deletion in SW872 cells to investigate cell cycle dysregulation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic systems for functional validation and drug screening. These models eliminate the confounding effects of genetic background variability seen in wild-type versus mutant comparisons.

CRISPR knockout and knock-in lines are used to validate the functional role of candidate driver genes. For example, knocking out TP53 in a wild-type background confirms its tumor suppressor activity, while introducing the KIT V560D mutation into GIST cells enables study of oncogenic signaling. Genome-wide CRISPR screens in isogenic lines can identify synthetic lethal partners (e.g., ATRX loss with PARP inhibition).

Isogenic pairs (e.g., TP53 wild-type vs. knockout) allow direct comparison of drug sensitivity. For instance, TP53-null osteosarcoma cells show increased sensitivity to MDM2 inhibitors. Resistance models are generated by chronic exposure to targeted agents (e.g., imatinib in KIT-mutant GIST cells), followed by CRISPR editing to confirm resistance mechanisms (e.g., secondary KIT mutations).

CRISPR screens in sarcoma cell lines identify genes whose loss confers sensitivity or resistance to therapies. For example, a screen in CDKN2A-deleted liposarcoma cells revealed CDK4/6 inhibitor sensitivity, validating CDKN2A loss as a predictive biomarker. Synthetic lethality screens (e.g., ATRX loss with PARP inhibitors) uncover novel therapeutic targets.